Get started
Markets US Stocks Health Technology Biotechnology

Axcella Health Inc AXLA

AXLA NASDAQ
AXLA
Axcella Health Inc NASDAQ
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals Analysis

AXLA Chart

Ideas

AXLA Bullish
AXLA
, 1DLong
AXLA: AXLA Bullish

MACD cross recently and the ADX is showing a relatively strong trend around 25 with the D+ well above D-. The two most recent candles are very bullish. The most recent making a wide ranging hammer that closed above the .38 fibonacci level and the 200 SMA. OBV is rising, confirming price action. AXLA has a relatively strong NEGATIVE correlation to all 3 major...

$AXLA is gonna fall today
AXLA
, 15Short
AXLA: $AXLA is gonna fall today

Pupm&Dump trading strategy idea. $AXLA is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $4,78; stop-loss — $5,17; take-profit — $4,02. Do not view this idea as a recommendation for trading or investing. It is...

AXLA
AXLA
, 1DLong
AXLA: AXLA

,,, it seems to me that for AXLA this lateral phase is the preparation to try to overcome the resistance placed at 6 usd

(BY Hidden Power)
AXLA
, 15
AXLA: (BY Hidden Power)

$AXLA Axcella Health $27million Insider buys
AXLA
, 1DLong
AXLA: $AXLA Axcella Health $27million Insider buys

$27,000,00 insider buys Nestle Health Science US Holdi 10% Owner May 18 Buy $4.75 1,936,842 $9,200,000 Epstein David R Director May 18 Buy $4.75 50,000 $237,500 Flagship Ventures Fund IV Gene 10% Owner May 18 Buy $4.75 3,800,000 $18,050,000

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Biotechnology
Axcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Breaking news

More news